Marinus is actively seeking strategic partnerships for the development and commercialization of its CNS-selective GABAA modulator, ganaxolone.

Our strategy is to leverage our core capabilities in formulation, clinical development and neuropsychiatry to achieve proof of efficacy and safety in target patient populations and engage with partners to advance late-stage development and commercialization globally.

For more information about strategic partnerships with Marinus Pharmaceuticals, please contact:

Lisa Caperelli
+1 (484)-801-4674